# A deep learning framework identifies dimensional representations of Alzheimer’s Disease from brain structure
Heterogeneity of brain diseases is a challenge for precision diagnosis/prognosis. We describe and validate Smile-GAN (SeMI-supervised cLustEring-Generative Adversarial Network), a semi-supervised deep-clustering method, which examines neuroanatomical heterogeneity contrasted against normal brain structure, to identify disease subtypes through neuroimaging signatures. When applied to regional volumes derived from T1-weighted MRI (two studies; 2,832 participants; 8,146 scans) including cognitively normal individuals and those with cognitive impairment and dementia, Smile-GAN identified four patterns or axes of neurodegeneration. Applying this framework to longitudinal data revealed two distinct progression pathways. Measures of expression of these patterns predicted the pathway and rate of future neurodegeneration. Pattern expression offered complementary performance to amyloid/tau in predicting clinical progression. These deep-learning derived biomarkers offer potential for precision diagnostics and targeted clinical trial recruitment.
>脑疾病的异质性是精确诊断/预后的挑战。 我们描述并验证了 Smile-GAN（SeMI 监督聚类生成对抗网络），这是一种半监督深度聚类方法，该方法检查与正常大脑结构对比的神经解剖异质性，以通过神经影像特征识别疾病亚型。 当应用于来自 T1 加权 MRI 的区域体积（两项研究；2,832 名参与者；8,146 次扫描）（包括认知正常个体和患有认知障碍和痴呆症的个体）时，Smile-GAN 识别出了四种神经退行性变的模式或轴。 将该框架应用于纵向数据揭示了两种不同的进展路径。 对这些模式表达的测量可以预测未来神经变性的途径和速率。 模式表达在预测临床进展方面与淀粉样蛋白/tau 蛋白具有互补的性能。 这些深度学习衍生的生物标志物为精确诊断和有针对性的临床试验招募提供了潜力。
# BRAIN NETWORK TRANSFORMER
Human brains are commonly modeled as networks of Regions of Interest (ROIs) and their connections for the understanding of brain functions and mental disorders. Recently, Transformer-based models have been studied over different types of data, including graphs, shown to bring performance gains widely. In this work, we study Transformer-based models for brain network analysis. Driven by the unique properties of data, we model brain networks as graphs with nodes of fixed size and order, which allows us to (1) use connection profiles as node features to provide natural and low-cost positional information and (2) learn pairwise connection strengths among ROIs with efficient attention weights across individuals that are predictive towards downstream analysis tasks. Moreover, we propose an ORTHONORMAL CLUSTERING READOUT operation based on selfsupervised soft clustering and orthonormal projection. This design accounts for the underlying functional modules that determine similar behaviors among groups of ROIs, leading to distinguishable cluster-aware node embeddings and informative graph embeddings. Finally, we re-standardize the evaluation pipeline on the only one publicly available large-scale brain network dataset of ABIDE, to enable meaningful comparison of different models. Experiment results show clear improvements of our proposed BRAIN NETWORK TRANSFORMER on both the public ABIDE and our restricted ABCD datasets. The implementation is available at https://github.com/Wayfear/BrainNetworkTransformer.
>人脑通常被建模为感兴趣区域 (ROI) 网络及其连接，以了解大脑功能和精神障碍。 最近，基于 Transformer 的模型已经在不同类型的数据（包括图形）上进行了研究，结果表明可以带来广泛的性能提升。 在这项工作中，我们研究基于 Transformer 的大脑网络分析模型。 在数据独特属性的驱动下，我们将大脑网络建模为具有固定大小和顺序的节点的图，这使我们能够（1）使用连接配置文件作为节点特征来提供自然且低成本的位置信息，以及（2）成对学习 ROI 之间的连接强度与个体之间的有效注意力权重可以预测下游分析任务。 此外，我们提出了一种基于自监督软聚类和正交投影的正交聚类读出操作。 这种设计考虑了确定 ROI 组之间相似行为的底层功能模块，从而产生可区分的集群感知节点嵌入和信息图嵌入。 最后，我们在 ABIDE 唯一一个公开的大规模脑网络数据集上重新标准化了评估流程，以便对不同模型进行有意义的比较。 实验结果表明，我们提出的 BRAIN NETWORK TRANSFORMER 在公共 ABIDE 和我们受限的 ABCD 数据集上都有明显的改进。 该实现可在 https://github.com/Wayfear/BrainNetworkTransformer 上找到。
# Brain age prediction using deep learning uncovers associated sequence variants
Machine learning algorithms can be trained to estimate age from brain structural MRI. The difference between an individual’s predicted and chronological age, predicted age difference (PAD), is a phenotype of relevance to aging and brain disease. Here, we present a new deep learning approach to predict brain age from a T1-weighted MRI. The method was trained on a dataset of healthy Icelanders and tested on two datasets, IXI and UK Biobank, utilizing transfer learning to improve accuracy on new sites. A genome-wide association study (GWAS) of PAD in the UK Biobank data (discovery set: N = 12378, replication set: N = 4456) yielded two sequence variants, rs1452628-T (β = 0.08, P = 1:15 * 10-9) and rs2435204-G (β = 0.102, P = 9:73 * 10^-12). The former is near KCNK2 and correlates with reduced sulcal width, whereas the latter correlates with reduced white matter surface area and tags a well-known inversion at 17q21.31 (H2)
>可以训练机器学习算法根据大脑结构 MRI 来估计年龄。 个体的预测年龄和实际年龄之间的差异，即预测年龄差异（PAD），是与衰老和脑部疾病相关的表型。 在这里，我们提出了一种新的深度学习方法，通过 T1 加权 MRI 预测大脑年龄。 该方法在健康冰岛人的数据集上进行了训练，并在 IXI 和 UK Biobank 两个数据集上进行了测试，利用迁移学习来提高新站点的准确性。 英国生物银行数据中的 PAD 全基因组关联研究 (GWAS)（发现集：N = 12378，复制集：N = 4456）产生了两个序列变异，rs1452628-T（β = 0.08，P = 1:15 * 10-9) 和 rs2435204-G (β = 0.102, P = 9:73 * 10^-12)。 前者靠近 KCNK2，与脑沟宽度减小相关，而后者与白质表面积减小相关，并在 17q21.31 (H2) 处标记了一个众所周知的倒位
# The Human Brainnetome Atlas: A New Brain Atlas Based on Connectional Architecture
The human brain atlases that allow correlating brain anatomy with psychological and cognitive functions are in transition from ex vivo histology-based printed atlases to digital brain maps providing multimodal in vivo information. Many current human brain atlases cover only specific structures, lack fine-grained parcellations, and fail to provide functionally important connectivity information. Using noninvasive multimodal neuroimaging techniques, we designed a connectivity-based parcellation framework that identifies the subdivisions of the entire human brain, revealing the in vivo connectivity architecture. The resulting human Brainnetome Atlas, with 210 cortical and 36 subcortical subregions, provides a fine-grained, cross-validated atlas and contains information on both anatomical and functional connections. Additionally, we further mapped the delineated structures to mental processes by reference to the BrainMap database. It thus provides an objective and stable starting point from which to explore the complex relationships between structure, connectivity, and function, and eventually improves understanding of how the human brain works. The human Brainnetome Atlas will be made freely available for download at http://atlas.brainnetome.org, so that whole brain parcellations, connections, and functional data will be readily available for researchers to use in their investigations into healthy and pathological states.
>允许将大脑解剖结构与心理和认知功能相关联的人脑图谱正在从基于离体组织学的印刷图谱过渡到提供多模式体内信息的数字脑图。 目前许多人类大脑图谱仅覆盖特定结构，缺乏细粒度的分区，并且无法提供功能上重要的连接信息。 使用非侵入性多模态神经成像技术，我们设计了一个基于连接的分割框架，该框架可以识别整个人脑的细分，揭示体内连接架构。 由此产生的人类脑网络组图谱包含 210 个皮质和 36 个皮质下分区，提供了细粒度、交叉验证的图谱，并包含有关解剖和功能连接的信息。 此外，我们参考 BrainMap 数据库进一步将所描绘的结构映射到心理过程。 因此，它提供了一个客观稳定的起点，可以探索结构、连接性和功能之间的复杂关系，并最终增进对人脑工作原理的理解。 人类脑网络组图谱将在 http://atlas.brainnetome.org 免费下载，以便研究人员可以轻松获得全脑分区、连接和功能数据，用于研究健康和病理状态。
# Derivation and utility of schizophrenia polygenic risk associated multimodal MRI frontotemporal network
Schizophrenia is a highly heritable psychiatric disorder characterized by widespread functional and structural brain abnormalities. However, previous association studies between MRI and polygenic risk were mostly ROI-based single modality analyses, rather than identifying brain-based multimodal predictive biomarkers. Based on schizophrenia polygenic risk scores (PRS) from healthy white people within the UK Biobank dataset (N = 22,459), we discovered a robust PRS-associated brain pattern with smaller gray matter volume and decreased functional activation in frontotemporal cortex, which distinguished schizophrenia from controls with >83% accuracy, and predicted cognition and symptoms across 4 independent schizophrenia cohorts. Further multi-disease comparisons demonstrated that these identified frontotemporal alterations were most severe in schizophrenia and schizo-affective patients, milder in bipolar disorder, and indistinguishable from controls in autism, depression and attention-deficit hyperactivity disorder. These findings indicate the potential of the identified PRS-associated multimodal frontotemporal network to serve as a trans-diagnostic gene intermediated brain biomarker specific to schizophrenia.
>精神分裂症是一种高度遗传的精神疾病，其特征是广泛的大脑功能和结构异常。 然而，之前的 MRI 与多基因风险之间的关联研究大多是基于 ROI 的单一模态分析，而不是识别基于大脑的多模态预测生物标志物。 根据英国生物银行数据集中健康白人的精神分裂症多基因风险评分 (PRS)（N = 22,459），我们发现了一种与 PRS 相关的稳健大脑模式，其灰质体积较小，额颞叶皮质功能激活减少，这将精神分裂症与精神分裂症区分开来。 控制准确度 >83%，并预测 4 个独立精神分裂症队列的认知和症状。 进一步的多种疾病比较表明，这些确定的额颞叶改变在精神分裂症和精神分裂情感患者中最为严重，在双相情感障碍中较轻，并且与自闭症、抑郁症和注意力缺陷多动障碍的对照者没有区别。 这些发现表明，已确定的 PRS 相关多模态额颞叶网络有可能作为精神分裂症特异性的跨诊断基因中介脑生物标志物。
# Discriminative Multi-Task Feature Selection for Multi-modality Based AD/MCI Classification
Recently, multi-task based feature selection methods have been used in multi-modality based classification of Alzheimer’s disease (AD) and its prodromal stage, i.e., mild cognitive impairment (MCI). However, in traditional multi-task feature selection methods, some useful discriminative information among subjects is usually not well mined for further improving the subsequent classification performance. Accordingly, in this paper, we propose a discriminative multi-task feature selection method to select the most discriminative features for multi-modality based classification of AD/MCI. Specifically, for each modality, we train a linear regression model using the corresponding modality of data, and further enforce the group-sparsity regularization on weights of those regression models for joint selection of common features across multiple modalities. Furthermore, we propose a discriminative regularization term based on the intra-class and inter-class Laplacian matrices to better use the discriminative information among subjects. We perform extensive experiments on 202 subjects from the baseline MRI and FDG-PET image data of the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The experimental results show that our proposed method improves the classification performance with the comparison to several state-ofthe-art methods for multi-modality based AD/MCI classification.
>最近，基于多任务的特征选择方法已被用于基于多模态的阿尔茨海默病（AD）及其前驱阶段，即轻度认知障碍（MCI）的分类。 然而，在传统的多任务特征选择方法中，通常没有很好地挖掘受试者之间的一些有用的判别信息以进一步提高后续的分类性能。 因此，在本文中，我们提出了一种判别性多任务特征选择方法，为基于多模态的 AD/MCI 分类选择最具判别性的特征。 具体来说，对于每种模态，我们使用相应的数据模态训练线性回归模型，并进一步对这些回归模型的权重实施组稀疏正则化，以联合选择跨多种模态的共同特征。 此外，我们提出了基于类内和类间拉普拉斯矩阵的判别正则化项，以更好地利用受试者之间的判别信息。 我们根据阿尔茨海默病神经影像计划 (ADNI) 的基线 MRI 和 FDG-PET 图像数据对 202 名受试者进行了广泛的实验。 实验结果表明，与基于多模态的 AD/MCI 分类的几种最先进的方法相比，我们提出的方法提高了分类性能。

# Genetic Influences on the Developing Young Brain and Risk for Neuropsychiatric Disorders
Imaging genetics provides an opportunity to discern associations between genetic variants and brain imaging phenotypes. Historically, the field has focused on adults and adolescents; very few imaging genetics studies have focused on brain development in infancy and early childhood (from birth to age six). This is an important knowledge gap as developmental changes in brain during the prenatal and early postnatal period are regulated by dynamic gene expression patterns that likely play an important role in establishing an individual’s risk for later psychiatric illness and neurodevelopmental disabilities. In this review, we summarize findings from imaging genetics studies spanning from early infancy to early childhood with a focus on studies examining genetic risk for neuropsychiatric disorders. We also introduce the Organization for Imaging Genomics in Infancy (ORIGINs), a working group of the ENIGMA (Enhancing NeuroImaging Genetics through Meta-Analysis) consortium, which was established to facilitate large-scale imaginggenetics studies in infancy and early childhood.
>成像遗传学提供了辨别遗传变异和大脑成像表型之间关联的机会。 从历史上看，该领域主要针对成人和青少年。 很少有影像遗传学研究关注婴儿期和幼儿期（从出生到六岁）的大脑发育。 这是一个重要的知识差距，因为产前和产后早期大脑的发育变化受到动态基因表达模式的调节，这些基因表达模式可能在确定个人以后患精神疾病和神经发育障碍的风险方面发挥重要作用。 在这篇综述中，我们总结了从婴儿早期到儿童早期的影像遗传学研究的结果，重点是检查神经精神疾病遗传风险的研究。 我们还介绍了婴儿期影像基因组学组织 (ORIGINs)，它是 ENIGMA（通过荟萃分析增强神经影像遗传学）联盟的一个工作组，成立的目的是促进婴儿期和幼儿期的大规模影像遗传学研究。

# Hierarchical Feature Representation and Multimodal Fusion with Deep Learning for AD/MCI Diagnosis
For the last decade, it has been shown that neuroimaging can be a potential tool for the diagnosis of Alzheimer’s Disease (AD) and its prodromal stage, Mild Cognitive Impairment (MCI), and also fusion of different modalities can further provide the complementary information to enhance diagnostic accuracy. Here, we focus on the problems of both feature representation and fusion of multimodal information from Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET). To our best knowledge, the previous methods in the literature mostly used hand-crafted features such as cortical thickness, gray matter densities from MRI, or voxel intensities from PET, and then combined these multimodal features by simply concatenating into a long vector or transforming into a higher-dimensional kernel space. In this paper, we propose a novel method for a high-level latent and shared feature representation from neuroimaging modalities via deep learning. Specifically, we use Deep Boltzmann Machine (DBM)1, a deep network with a restricted Boltzmann machine as a building block, to find a latent hierarchical feature representation from a 3D patch, and then devise a systematic method for a joint feature representation from the paired patches of MRI and PET with a multimodal DBM. To validate the effectiveness of the proposed method, we performed experiments on ADNI dataset and compared with the state-of-the-art methods. In three binary classification problems of AD vs. healthy Normal Control (NC), MCI vs. NC, and MCI converter vs. MCI non-converter, we obtained the maximal accuracies of 95.35%, 85.67%, and 74.58%, respectively, outperforming the competing methods. By visual inspection of the trained model, we observed that the proposed method could hierarchically discover the complex latent patterns inherent in both MRI and PET.
> 在过去的十年中，研究表明神经影像学可以成为诊断阿尔茨海默病（AD）及其前驱阶段、轻度认知障碍（MCI）的潜在工具，并且不同模式的融合可以进一步提供补充信息 提高诊断准确性。 在这里，我们重点关注磁共振成像（MRI）和正电子发射断层扫描（PET）的多模态信息的特征表示和融合问题。 据我们所知，文献中以前的方法大多使用手工制作的特征，例如皮质厚度、MRI 的灰质密度或 PET 的体素强度，然后通过简单地连接成长向量或转换成 高维核空间。 在本文中，我们提出了一种通过深度学习从神经影像模式中进行高级潜在和共享特征表示的新方法。 具体来说，我们使用深度玻尔兹曼机（DBM），一种以受限玻尔兹曼机为构建块的深层网络，从 3D 补丁中找到潜在的分层特征表示，然后设计一种系统方法，用于从 MRI 和 PET 与多模式 DBM 配对。 为了验证所提出方法的有效性，我们在 ADNI 数据集上进行了实验，并与最先进的方法进行了比较。 在 AD 与健康正常对照 (NC)、MCI 与 NC、MCI 转换器与 MCI 非转换器这三个二元分类问题中，我们分别获得了 95.35%、85.67% 和 74.58% 的最大准确率，优于其他分类问题 竞争方法。 通过对训练模型的目视检查，我们观察到所提出的方法可以分层发现 MRI 和 PET 中固有的复杂潜在模式。

# Joint Embedding of Structural and Functional Brain Networks with Graph Neural Networks for Mental Illness Diagnosis
Multimodal brain networks characterize complex connectivities among different brain regions from both structural and functional aspects and provide a new means for mental disease analysis. Recently, Graph Neural Networks (GNNs) have become a de facto model for analyzing graph-structured data. However, how to employ GNNs to extract effective representations from brain networks in multiple modalities remains rarely explored. Moreover, as brain networks provide no initial node features, how to design informative node attributes and leverage edge weights for GNNs to learn is left unsolved. To this end, we develop a novel multiview GNN for multimodal brain networks. In particular, we treat each modality as a view for brain networks and employ contrastive learning for multimodal fusion. Then, we propose a GNN model which takes advantage of the message passing scheme by propagating messages based on degree statistics and brain region connectivities. Extensive experiments on two real-world disease datasets (HIV and Bipolar) demonstrate the effectiveness of our proposed method over state-of-the-art baselines.
>多模态脑网络从结构和功能方面表征了不同脑区之间的复杂连接，为精神疾病分析提供了新的手段。 最近，图神经网络（GNN）已成为分析图结构数据的事实上的模型。 然而，如何利用 GNN 从多种模式的大脑网络中提取有效的表示仍然很少被探索。 此外，由于大脑网络不提供初始节点特征，因此如何设计信息丰富的节点属性并利用边缘权重供 GNN 学习仍悬而未决。 为此，我们开发了一种用于多模式大脑网络的新型多视图 GNN。 特别是，我们将每种模态视为大脑网络的视图，并采用对比学习进行多模态融合。 然后，我们提出了一种 GNN 模型，该模型利用消息传递方案，根据度统计和大脑区域连接性传播消息。 对两个现实世界疾病数据集（艾滋病毒和双相情感障碍）的广泛实验证明了我们提出的方法相对于最先进基线的有效性。

# Multimodal Classification of Alzheimer’s Disease and Mild Cognitive Impairment
Effective and accurate diagnosis of Alzheimer’s disease (AD), as well as its prodromal stage (i.e., mild cognitive impairment (MCI)), has attracted more and more attentions recently. So far, multiple biomarkers have been shown sensitive to the diagnosis of AD and MCI, i.e., structural MR imaging (MRI) for brain atrophy measurement, functional imaging (e.g., FDG-PET) for hypometabolism quantification, and cerebrospinal fluid (CSF) for quantification of specific proteins. However, most existing research focuses on only a single modality of biomarkers for diagnosis of AD and MCI, although recent studies have shown that different biomarkers may provide complementary information for diagnosis of AD and MCI. In this paper, we propose to combine three modalities of biomarkers, i.e., MRI, FDG-PET, and CSF biomarkers, to discriminate between AD (or MCI) and healthy controls, using a kernel combination method. Specifically, ADNI baseline MRI, FDG-PET, and CSF data from 51 AD patients, 99 MCI patients (including 43 MCI converters who had converted to AD within 18 months and 56 MCI nonconverters who had not converted to AD within 18 months), and 52 healthy controls are used for development and validation of our proposed multimodal classification method. In particular, for each MR or FDG-PET image, 93 volumetric features are extracted from the 93 regions of interest (ROIs), automatically labeled by an atlas warping algorithm. For CSF biomarkers, their original values are directly used as features. Then, a linear support vector machine (SVM) is adopted to evaluate the classification accuracy, using a 10-fold cross-validation. As a result, for classifying AD from healthy controls, we achieve a classification accuracy of 93.2% (with a sensitivity of 93% and a specificity of 93.3%) when combining all three modalities of biomarkers, and only 86.5% when using even the best individual modality of biomarkers. Similarly, for classifying MCI from healthy controls, we achieve a classification accuracy of 76.4% (with a sensitivity of 81.8% and a specificity of 66%) for our combined method, and only 72% even using the best individual modality of biomarkers. Further analysis on MCI sensitivity of our combined method indicates that 91.5% of MCI converters and 73.4% of MCI non-converters are correctly classified. Moreover, we also evaluate the classification performance when employing a feature selection method to select the most discriminative MR and FDG-PET features. Again, our combined method shows considerably better performance, compared to the case of using an individual modality of biomarkers
>阿尔茨海默病（AD）及其前驱阶段（即轻度认知障碍（MCI））的有效、准确诊断近年来引起了越来越多的关注。 迄今为止，多种生物标志物已被证明对 AD 和 MCI 的诊断敏感，即用于脑萎缩测量的结构磁共振成像 (MRI)、用于量化低代谢的功能成像（例如 FDG-PET）以及用于量化低代谢的脑脊液 (CSF)。 特定蛋白质的定量。 然而，大多数现有研究仅关注用于诊断 AD 和 MCI 的单一生物标志物，尽管最近的研究表明不同的生物标志物可以为 AD 和 MCI 的诊断提供补充信息。 在本文中，我们建议结合三种生物标志物模式，即 MRI、FDG-PET 和 CSF 生物标志物，使用核组合方法来区分 AD（或 MCI）和健康对照。 具体来说，来自 51 名 AD 患者、99 名 MCI 患者（包括 43 名在 18 个月内转化为 AD 的 MCI 转化者和 56 名在 18 个月内未转化为 AD 的 MCI 未转化者）的 ADNI 基线 MRI、FDG-PET 和 CSF 数据，以及 52 个健康对照用于开发和验证我们提出的多模式分类方法。 特别是，对于每个 MR 或 FDG-PET 图像，从 93 个感兴趣区域 (ROI) 中提取 93 个体积特征，并通过图集扭曲算法自动标记。 对于CSF生物标志物，直接使用其原始值作为特征。 然后，采用线性支持向量机（SVM）通过10倍交叉验证来评估分类精度。 因此，在将 AD 与健康对照进行分类时，当结合所有三种生物标志物模式时，我们的分类准确度为 93.2%（敏感性为 93%，特异性为 93.3%），而即使使用最好的生物标记物，分类准确度也仅为 86.5% 生物标志物的个体模式。 同样，对于健康对照中的 MCI 进行分类，我们的组合方法的分类准确度为 76.4%（敏感性为 81.8%，特异性为 66%），即使使用最佳的生物标志物个体模式，分类准确度也仅为 72%。 对我们的组合方法的 MCI 敏感性的进一步分析表明，91.5% 的 MCI 转化者和 73.4% 的 MCI 非转化者被正确分类。 此外，我们还评估了采用特征选择方法来选择最具辨别力的 MR 和 FDG-PET 特征时的分类性能。 同样，与使用单独的生物标志物模式的情况相比，我们的组合方法显示出明显更好的性能

# Multi-cohort and longitudinal Bayesian clustering study of stage and subtype in Alzheimer’s disease
Understanding Alzheimer’s disease (AD) heterogeneity is important for understanding the underlying pathophysiological mechanisms of AD. However, AD atrophy subtypes may reflect different disease stages or biologically distinct subtypes. Here we use longitudinal magnetic resonance imaging data (891 participants with AD dementia, 305 healthy control participants) from four international cohorts, and longitudinal clustering to estimate differential atrophy trajectories from the age of clinical disease onset. Our findings (in amyloid-β positive AD patients) show five distinct longitudinal patterns of atrophy with different demographical and cognitive characteristics. Some previously reported atrophy subtypes may reflect disease stages rather than distinct subtypes. The heterogeneity in atrophy rates and cognitive decline within the five longitudinal atrophy patterns, potentially expresses a complex combination of protective/risk factors and concomitant non-AD pathologies. By alternating between the cross-sectional and longitudinal understanding of AD subtypes these analyses may allow better understanding of disease heterogeneity
>了解阿尔茨海默病 (AD) 异质性对于了解 AD 潜在的病理生理机制非常重要。 然而，AD 萎缩亚型可能反映不同的疾病阶段或生物学上不同的亚型。 在这里，我们使用来自四个国际队列的纵向磁共振成像数据（891 名患有 AD 痴呆症的参与者，305 名健康对照参与者）和纵向聚类来估计临床疾病发病年龄的差异萎缩轨迹。 我们的研究结果（β-淀粉样蛋白阳性 AD 患者）显示出五种不同的纵向萎缩模式，具有不同的人口和认知特征。 一些先前报道的萎缩亚型可能反映疾病阶段而不是不同的亚型。 五种纵向萎缩模式内萎缩率和认知能力下降的异质性，可能表达了保护性/危险因素和伴随的非 AD 病理的复杂组合。 通过交替对 AD 亚型的横截面和纵向理解，这些分析可以更好地理解疾病异质性

# Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease
Many machine learning and pattern classification methods have been applied to the diagnosis of Alzheimer's disease (AD) and its prodromal stage, i.e., mild cognitive impairment (MCI). Recently, rather than predicting categorical variables as in classification, several pattern regression methods have also been used to estimate continuous clinical variables from brain images. However, most existing regression methods focus on estimating multiple clinical variables separately and thus cannot utilize the intrinsic useful correlation information among different clinical variables. On the other hand, in those regression methods, only a single modality of data (usually only the structural MRI) is often used, without considering the complementary information that can be provided by different modalities. In this paper, we propose a general methodology, namely multimodal multi-task (M3T) learning, to jointly predict multiple variables from multi-modal data. Here, the variables include not only the clinical variables used for regression but also the categorical variable used for classification, with different tasks corresponding to prediction of different variables. Specifically, our method contains two key components, i.e., (1) a multi-task feature selection which selects the common subset of relevant features for multiple variables from each modality, and (2) a multi-modal support vector machine which fuses the above-selected features from all modalities to predict multiple (regression and classification) variables. To validate our method, we perform two sets of experiments on ADNI baseline MRI, FDG-PET, and cerebrospinal fluid (CSF) data from 45 AD patients, 91 MCI patients, and 50 healthy controls (HC). In the first set of experiments, we estimate two clinical variables such as Mini Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), as well as one categorical variable (with value of ‘AD’, ‘MCI’ or ‘HC’), from the baseline MRI, FDG-PET, and CSF data. In the second set of experiments, we predict the 2-year changes of MMSE and ADAS-Cog scores and also the conversion of MCI to AD from the baseline MRI, FDG-PET, and CSF data. The results on both sets of experiments demonstrate that our proposed M3T learning scheme can achieve better performance on both regression and classification tasks than the conventional learning methods.
>许多机器学习和模式分类方法已应用于阿尔茨海默病（AD）及其前驱阶段，即轻度认知障碍（MCI）的诊断。 最近，几种模式回归方法也被用来从大脑图像中估计连续的临床变量，而不是像分类中那样预测分类变量。 然而，大多数现有的回归方法侧重于分别估计多个临床变量，因此无法利用不同临床变量之间内在有用的相关信息。 另一方面，在这些回归方法中，通常仅使用单一模态的数据（通常仅结构 MRI），而没有考虑不同模态可以提供的补充信息。 在本文中，我们提出了一种通用方法，即多模态多任务（M3T）学习，用于从多模态数据中联合预测多个变量。 这里的变量不仅包括用于回归的临床变量，还包括用于分类的分类变量，不同的任务对应于不同变量的预测。 具体来说，我们的方法包含两个关键组件，即（1）多任务特征选择，为每个模态的多个变量选择相关特征的公共子集，以及（2）融合上述内容的多模态支持向量机 -从所有模式中选择特征来预测多个（回归和分类）变量。 为了验证我们的方法，我们对来自 45 名 AD 患者、91 名 MCI 患者和 50 名健康对照 (HC) 的 ADNI 基线 MRI、FDG-PET 和脑脊液 (CSF) 数据进行了两组实验。 在第一组实验中，我们估计了两个临床变量，例如简易精神状态检查（MMSE）和阿尔茨海默病评估量表-认知子量表（ADAS-Cog），以及一个分类变量（值为“AD”，“ MCI' 或 'HC'），来自基线 MRI、FDG-PET 和 CSF 数据。 在第二组实验中，我们根据基线 MRI、FDG-PET 和 CSF 数据预测 MMSE 和 ADAS-Cog 评分的 2 年变化以及 MCI 到 AD 的转换。 两组实验的结果表明，我们提出的 M3T 学习方案可以在回归和分类任务上取得比传统学习方法更好的性能。

# Identifying Alzheimer’s Disease-Related Brain Regions from Multi-Modality Neuroimaging Data using Sparse Composite Linear Discrimination Analysis
Diagnosis of Alzheimer’s disease (AD) at the early stage of the disease development is of great clinical importance. Current clinical assessment that relies primarily on cognitive measures proves low sensitivity and specificity. The fast growing neuroimaging techniques hold great promise. Research so far has focused on single neuroimaging modality. However, as different modalities provide complementary measures for the same disease pathology, fusion of multi-modality data may increase the statistical power in identification of disease-related brain regions. This is especially true for early AD, at which stage the disease-related regions are most likely to be weakeffect regions that are difficult to be detected from a single modality alone. We propose a sparse composite linear discriminant analysis model (SCLDA) for identification of disease-related brain regions of early AD from multi-modality data. SCLDA uses a novel formulation that decomposes each LDA parameter into a product of a common parameter shared by all the modalities and a parameter specific to each modality, which enables joint analysis of all the modalities and borrowing strength from one another. We prove that this formulation is equivalent to a penalized likelihood with non-convex regularization, which can be solved by the DC (difference of convex functions) programming. We show that in using the DC programming, the property of the nonconvex regularization in terms of preserving weak-effect features can be nicely revealed. We perform extensive simulations to show that SCLDA outperforms existing competing algorithms on feature selection, especially on the ability for identifying weak-effect features. We apply SCLDA to the Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) images of 49 AD patients and 67 normal controls (NC). Our study identifies disease-related brain regions consistent with findings in the AD literature.
>在疾病发展的早期阶段诊断阿尔茨海默病（AD）具有重要的临床意义。 目前主要依赖于认知测量的临床评估证明其敏感性和特异性较低。 快速发展的神经影像技术前景广阔。 迄今为止的研究主要集中在单一的神经影像学模式上。 然而，由于不同的模式为相同的疾病病理学提供了互补的测量，多模式数据的融合可能会增加识别疾病相关大脑区域的统计能力。 对于早期AD尤其如此，在该阶段，与疾病相关的区域最有可能是弱效应区域，难以仅通过单一方式检测到。 我们提出了一种稀疏复合线性判别分析模型（SCLDA），用于从多模态数据中识别早期 AD 疾病相关的大脑区域。 SCLDA 使用一种新颖的公式，将每个 LDA 参数分解为所有模态共享的公共参数和每种模态特定的参数的乘积，这使得能够对所有模态进行联合分析并相互借用力量。 我们证明这个公式等价于非凸正则化的惩罚似然，可以通过 DC（凸函数差分）编程来解决。 我们证明，在使用 DC 编程时，可以很好地揭示非凸正则化在保留弱效应特征方面的特性。 我们进行了大量的模拟，结果表明 SCLDA 在特征选择方面优于现有的竞争算法，尤其是在识别弱效应特征的能力方面。 我们将 SCLDA 应用于 49 名 AD 患者和 67 名正常对照 (NC) 的磁共振成像 (MRI) 和正电子发射断层扫描 (PET) 图像。 我们的研究确定了与疾病相关的大脑区域，与 AD 文献中的发现一致。

# Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference
The heterogeneity of neurodegenerative diseases is a key confound to disease understanding and treatment development, as study cohorts typically include multiple phenotypes on distinct disease trajectories. Here we introduce a machine-learning technique—Subtype and Stage Inference (SuStaIn)—able to uncover data-driven disease phenotypes with distinct temporal progression patterns, from widely available cross-sectional patient studies. Results from imaging studies in two neurodegenerative diseases reveal subgroups and their distinct trajectories of regional neurodegeneration. In genetic frontotemporal dementia, SuStaIn identifies genotypes from imaging alone, validating its ability to identify subtypes; further the technique reveals within-genotype heterogeneity. In Alzheimer’s disease, SuStaIn uncovers three subtypes, uniquely characterising their temporal complexity. SuStaIn provides finegrained patient stratification, which substantially enhances the ability to predict conversion between diagnostic categories over standard models that ignore subtype (p = 7.18 × 10-4) or temporal stage (p = 3.96 × 10-5). SuStaIn offers new promise for enabling disease subtype discovery and precision medicine
>神经退行性疾病的异质性是疾病理解和治疗开发的一个关键混淆因素，因为研究队列通常包括不同疾病轨迹的多种表型。 在这里，我们介绍一种机器学习技术——亚型和阶段推断（SuStaIn）——能够从广泛可用的横断面患者研究中揭示具有不同时间进展模式的数据驱动的疾病表型。 两种神经退行性疾病的影像学研究结果揭示了区域神经退行性疾病的亚组及其独特的轨迹。 在遗传性额颞叶痴呆中，SuStaIn 仅通过影像识别基因型，验证了其识别亚型的能力； 该技术进一步揭示了基因型内的异质性。 在阿尔茨海默病中，SuStaIn 发现了三种亚型，独特地表征了它们的时间复杂性。 SuStaIn 提供细粒度的患者分层，与忽略亚型 (p = 7.18 × 10-4) 或时间阶段 (p = 3.96 × 10-5) 的标准模型相比，大大增强了预测诊断类别之间转换的能力。 SuStaIn 为疾病亚型发现和精准医疗提供了新的希望。

# Genome-wide association studies of brain imaging phenotypes in UK Biobank
The genetic architecture of brain structure and function is largely unknown. To investigate this, we carried out genomewide association studies of 3,144 functional and structural brain imaging phenotypes from UK Biobank (discovery dataset 8,428 subjects). Here we show that many of these phenotypes are heritable. We identify 148 clusters of associations between single nucleotide polymorphisms and imaging phenotypes that replicate at P< 0.05, when we would expect 21 to replicate by chance. Notable significant, interpretable associations include: iron transport and storage genes, related to magnetic susceptibility of subcortical brain tissue; extracellular matrix and epidermal growth factor genes, associated with white matter micro-structure and lesions; genes that regulate mid-line axon development, associated with organization of the pontine crossing tract; and overall 17 genes involved in development, pathway signalling and plasticity. Our results provide insights into the genetic architecture of the brain that are relevant to neurological and psychiatric disorders, brain development and ageing.
>大脑结构和功能的遗传结构在很大程度上是未知的。 为了研究这一点，我们对英国生物银行的 3,144 个功能和结构脑成像表型进行了全基因组关联研究（发现数据集 8,428 名受试者）。 在这里，我们表明许多这些表型是可遗传的。 我们确定了 148 个关联簇单核苷酸多态性和以 P < 0.05 复制的成像表型之间的差异，而我们期望21 偶然复制。 值得注意的、可解释的关联包括：铁运输和储存基因，与皮层下脑组织磁化率有关； 细胞外基质和表皮生长因子基因，与白质微结构和病变相关； 调节中线轴突发育的基因，相关与脑桥交叉道的组织； 总共 17 个基因涉及发育、通路信号传导和可塑性。 我们的结果提供了对与神经系统和神经系统相关的大脑遗传结构的见解。精神疾病、大脑发育和衰老。

# Multimodal population brain imaging in the UK Biobank prospective epidemiological study
Medical imaging has enormous potential for early disease prediction, but is impeded by the difficulty and expense of acquiring datasets prior to symptom onset. UK Biobank aims to address this problem directly by acquiring high quality, consistently acquired imaging data from 100,000 predominantly healthy participants, with health outcomes tracked over coming decades. The brain imaging includes structural, diffusion and functional modalities. Along with body and cardiac imaging, genetics, lifestyle measures, biological phenotyping and health records, this is expected to enable discovery of imaging markers of a broad range of diseases at their earliest stages, as well as provide unique insight into disease mechanisms. We describe UK Biobank brain imaging, and present results derived from the first 5,000 participants’ data release. Although that covers just 5% of the ultimate cohort, it already yields a rich range of associations between brain imaging and other measures collected by UK Biobank.
>医学成像在早期疾病预测方面具有巨大潜力，但由于在症状出现之前获取数据集的难度和费用而受到阻碍。 英国生物银行旨在通过从 100,000 名主要健康参与者那里获取高质量、持续采集的成像数据来直接解决这一问题，并跟踪未来几十年的健康结果。 脑成像包括结构、扩散和功能模式。 与身体和心脏成像、遗传学、生活方式测量、生物表型和健康记录一起，这预计将能够在早期阶段发现广泛疾病的成像标志物，并提供对疾病机制的独特见解。 我们描述了英国生物银行的大脑成像，并展示了前 5,000 名参与者的数据发布的结果。 尽管这仅覆盖了最终队列的 5%，但它已经在大脑成像与英国生物银行收集的其他指标之间产生了丰富的关联。

# UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age
• UK Biobank is a very large and detailed prospective study with over 500,000 participants aged 40–69 years when recruited in 2006–2010.

• The study has collected and continues to collect extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometry, multimodal imaging, genome-wide genotyping and longitudinal follow-up for a wide range of health-related outcomes.

• Wide consultation; input from scientific, management, legal, and ethical partners; and industrial-scale, centralised processes have been essential to the development of this resource.

• UK Biobank is available for open access, without the need for collaboration, to any bonafide researcher who wishes to use it to conduct health-related research for the benefit of the public.
>• 英国生物银行是一项规模非常大、详细的前瞻性研究，2006-2010 年招募了超过 500,000 名年龄在 40-69 岁的参与者
>• 该研究已经并将继续收集有关参与者的广泛表型和基因型详细信息，包括来自问卷调查、物理测量、样本分析、加速测量、多模态成像、全基因组基因分型和针对广泛健康人群的纵向随访的数据。 相关结果。
>• 广泛咨询； 来自科学、管理、法律和道德合作伙伴的意见； 工业规模的集中流程对于这种资源的开发至关重要。
>• 英国生物银行可以向任何希望利用其进行健康相关研究以造福公众的真诚研究人员开放访问，无需合作。


# An expanded set of genome-wide association studies of brain imaging phenotypes in UK Biobank
UK Biobank is a major prospective epidemiological study, including multimodal brain imaging, genetics and ongoing health outcomes. Previously, we published genome-wide associations of 3,144 brain imaging-derived phenotypes, with a discovery sample of 8,428 subjects. Here we present a new open resource of GWAS summary statistics, using the 2020 data release, almost tripling the discovery sample size. We now include the X chromosome, and new classes of image derived phenotypes (subcortical volumes and tissue contrast). Previously we had found 148 replicated clusters of associations between genetic variants and imaging phenotypes; here we find 692, including 12 on the X chromosome. We describe some of the newly found associations, focussing on the X chromosome and autosomal associations involving the new classes of imagingderived phenotypes. Our novel associations implicate e.g. pathways involved in the rare X-linked syndrome STAR (syndactyly, telecanthus and anogenital and renal malformations), Alzheimer’s disease and mitochondrial disorders
>英国生物银行是一项重要的前瞻性流行病学研究，包括多模式脑成像、
遗传学和持续的健康结果。 此前，我们发表了全基因组关联3,144 种脑成像衍生表型，发现样本包含 8,428 名受试者。 在这里，我们提出一个新的GWAS汇总统计开放资源，使用2020年发布的数据，几乎将发现样本量增加两倍。 我们现在包括 X 染色体和新的图像类别衍生表型（皮层下体积和组织对比）。 之前我们已经找到了 148遗传变异和成像表型之间的重复关联簇； 在这里我们发现692个，其中X染色体上有12个。 我们描述了一些新发现的关联，重点关注涉及新型成像衍生表型的 X 染色体和常染色体关联。 我们新颖的联想暗示着，例如 参与罕见 X 连锁的途径STAR 综合征（并指、远眦、肛门生殖器和肾脏畸形）、阿尔茨海默病疾病和线粒体疾病